JP7049349B2 - ベンジルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 - Google Patents
ベンジルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 Download PDFInfo
- Publication number
- JP7049349B2 JP7049349B2 JP2019540030A JP2019540030A JP7049349B2 JP 7049349 B2 JP7049349 B2 JP 7049349B2 JP 2019540030 A JP2019540030 A JP 2019540030A JP 2019540030 A JP2019540030 A JP 2019540030A JP 7049349 B2 JP7049349 B2 JP 7049349B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- replaced
- cycloalkyl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17153386.2 | 2017-01-26 | ||
| EP17153386 | 2017-01-26 | ||
| PCT/EP2018/051385 WO2018138028A1 (en) | 2017-01-26 | 2018-01-22 | Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505393A JP2020505393A (ja) | 2020-02-20 |
| JP2020505393A5 JP2020505393A5 (https=) | 2021-01-21 |
| JP7049349B2 true JP7049349B2 (ja) | 2022-04-06 |
Family
ID=57906577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019540030A Active JP7049349B2 (ja) | 2017-01-26 | 2018-01-22 | ベンジルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10793530B2 (https=) |
| EP (1) | EP3573959B1 (https=) |
| JP (1) | JP7049349B2 (https=) |
| CN (1) | CN110248929B (https=) |
| WO (1) | WO2018138028A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110214135B (zh) * | 2017-01-26 | 2023-02-21 | 勃林格殷格翰国际有限公司 | 茚满基氨基吡嗪基环丙烷羧酸、药物组合物及其用途 |
| EP3573959B1 (en) * | 2017-01-26 | 2021-07-28 | Boehringer Ingelheim International GmbH | Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| CN110177773B (zh) * | 2017-01-26 | 2023-08-25 | 勃林格殷格翰国际有限公司 | 苄基氨基吡啶基环丙烷羧酸、其药物组合物及其用途 |
| JP7050792B2 (ja) * | 2017-01-26 | 2022-04-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 |
| US10913720B2 (en) | 2017-01-26 | 2021-02-09 | Boehringer Ingelheim International Gmbh | Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| TWI707849B (zh) | 2018-02-13 | 2020-10-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| EP3820572B1 (en) | 2018-07-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| US11808675B2 (en) * | 2019-06-13 | 2023-11-07 | Agilent Technologies, Inc. | Room temperature methods for preparing biological analytes |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| IL295825A (en) | 2020-02-28 | 2022-10-01 | Kallyope Inc | gpr40 agonists |
| WO2021236617A1 (en) | 2020-05-19 | 2021-11-25 | Kallyope, Inc. | Ampk activators |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005051890A1 (en) | 2003-11-19 | 2005-06-09 | Smithkline Beecham Corporation | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40 |
| JP2006522130A (ja) | 2003-04-03 | 2006-09-28 | メルク エンド カムパニー インコーポレーテッド | ナトリウムチャンネル遮断薬としてのビアリール置換ピラゾール |
| WO2007013689A1 (ja) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | シクロプロパンカルボン酸化合物 |
| WO2008066097A1 (fr) | 2006-12-01 | 2008-06-05 | Astellas Pharma Inc. | Dérivé d'acide carboxylique |
| JP2012508260A (ja) | 2008-11-10 | 2012-04-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼの阻害剤として有用な化合物 |
| JP2019532110A (ja) | 2016-10-25 | 2019-11-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物および使用 |
| JP2020505402A (ja) | 2017-01-26 | 2020-02-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルオキシピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 |
| JP2020505400A (ja) | 2017-01-26 | 2020-02-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 |
| JP2020505394A (ja) | 2017-01-26 | 2020-02-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | インダニルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 |
| JP2020514315A (ja) | 2017-01-26 | 2020-05-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US628476A (en) | 1898-03-18 | 1899-07-11 | Joseph Howard Kirk | Junction of cycle, motor-car, or other frames, &c. |
| US2505322A (en) | 1945-09-14 | 1950-04-25 | Gibson Refrigerator Co | Refrigerator cabinet |
| US2560111A (en) | 1946-11-07 | 1951-07-10 | Raymond T Levine | Buffing chuck |
| US2656003A (en) | 1948-02-27 | 1953-10-20 | Inst Of Inventive Res | High explosive disk-shaped charge for seismic exploration |
| US2727340A (en) | 1953-08-31 | 1955-12-20 | Alfred S Zanotta | Portable tool for reconditioning crane rails |
| US5356287A (en) | 1987-03-16 | 1994-10-18 | Mcintyre Kevin M | Simulating presence |
| AU2003277576A1 (en) | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| EP1630152A4 (en) | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | CONDENSED CYCLIC COMPOUND |
| US7786165B2 (en) | 2004-03-15 | 2010-08-31 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
| DE102004017930A1 (de) | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| JP2008530162A (ja) | 2005-02-15 | 2008-08-07 | グラクソ グループ リミテッド | グルタミン酸受容体を増強する化合物および医薬におけるそれらの使用 |
| WO2006103503A1 (en) | 2005-03-28 | 2006-10-05 | Pfizer Japan Inc. | Substituted aryloxoethyl cyclopropanecarboxamide compounds as vr1 receptor antagonists |
| US7664629B2 (en) | 2005-07-19 | 2010-02-16 | Xerox Corporation | Second language writing advisor |
| WO2007033002A1 (en) | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| JP2009530237A (ja) | 2006-03-15 | 2009-08-27 | ノイロサーチ アクティーゼルスカブ | キナゾリノン及びカリウムチャネル活性化剤としてのその使用 |
| EP2006271A4 (en) | 2006-03-30 | 2011-08-10 | Asahi Kasei Pharma Corp | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF |
| BRPI0713378A8 (pt) | 2006-06-27 | 2018-01-02 | Takeda Pharmaceutical | composto, pró-droga, modulador da função do receptor gpr40, agente farmacêutico uso do composto, e, método de produção de uma forma opticamente ativa de um composto |
| NZ588983A (en) | 2008-06-25 | 2011-11-25 | Daiichi Sankyo Co Ltd | Carboxylic acid compound |
| ES2345916B1 (es) | 2008-10-14 | 2011-09-14 | Clipdorfix, S.L. | Dispositivo de fijacion liberable de elementos adosados. |
| AU2009303475B2 (en) | 2008-10-15 | 2012-09-13 | Amgen Inc. | Spirocyclic GPR40 modulators |
| WO2010051819A1 (en) | 2008-11-10 | 2010-05-14 | Neurosearch A/S | Novel 2,3-diamino-quinazolinone derivatives and their medical use |
| WO2010143733A1 (en) | 2009-06-09 | 2010-12-16 | Takeda Pharmaceutical Company Limited | Novel fused cyclic compound and use thereof |
| WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| CA2799414A1 (en) | 2010-05-18 | 2011-11-24 | Merck Sharp & Dohme Corp. | Spiro isoxazoline compounds as sstr5 antagonists |
| TW201643169A (zh) | 2010-07-09 | 2016-12-16 | 艾伯維股份有限公司 | 作為s1p調節劑的螺-哌啶衍生物 |
| AR084050A1 (es) | 2010-12-01 | 2013-04-17 | Boehringer Ingelheim Int | Acidos indaniloxidihidrobenzofuranilaceticos |
| US8642585B2 (en) | 2012-03-26 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
| US8633182B2 (en) | 2012-05-30 | 2014-01-21 | Boehringer Ingelheim International Gmbh | Indanyloxyphenylcyclopropanecarboxylic acids |
| WO2014019186A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| PE20150968A1 (es) | 2012-11-28 | 2015-07-09 | Boehringer Ingelheim Int | Nuevos acidos indaniloxi dihidrobenzofuranil aceticos |
| JP6283862B2 (ja) | 2012-12-07 | 2018-02-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規インダニルオキシジヒドロベンゾフラニル酢酸 |
| EP2963027B1 (en) | 2013-02-28 | 2018-12-26 | TiumBio Co., Ltd. | Tricyclic compound and use thereof |
| CN105473595A (zh) | 2013-08-23 | 2016-04-06 | 福建海西新药创制有限公司 | 治疗糖尿病的羧酸化合物 |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| EP3573959B1 (en) * | 2017-01-26 | 2021-07-28 | Boehringer Ingelheim International GmbH | Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| US10550127B1 (en) | 2017-02-08 | 2020-02-04 | Boehringer Ingelheim International Gmbh | Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes |
-
2018
- 2018-01-22 EP EP18703221.4A patent/EP3573959B1/en active Active
- 2018-01-22 US US16/479,226 patent/US10793530B2/en active Active
- 2018-01-22 WO PCT/EP2018/051385 patent/WO2018138028A1/en not_active Ceased
- 2018-01-22 CN CN201880007969.8A patent/CN110248929B/zh active Active
- 2018-01-22 JP JP2019540030A patent/JP7049349B2/ja active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006522130A (ja) | 2003-04-03 | 2006-09-28 | メルク エンド カムパニー インコーポレーテッド | ナトリウムチャンネル遮断薬としてのビアリール置換ピラゾール |
| WO2005051890A1 (en) | 2003-11-19 | 2005-06-09 | Smithkline Beecham Corporation | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40 |
| WO2007013689A1 (ja) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | シクロプロパンカルボン酸化合物 |
| WO2008066097A1 (fr) | 2006-12-01 | 2008-06-05 | Astellas Pharma Inc. | Dérivé d'acide carboxylique |
| JP2012508260A (ja) | 2008-11-10 | 2012-04-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼの阻害剤として有用な化合物 |
| JP2019532110A (ja) | 2016-10-25 | 2019-11-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物および使用 |
| JP2020505402A (ja) | 2017-01-26 | 2020-02-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルオキシピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 |
| JP2020505400A (ja) | 2017-01-26 | 2020-02-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 |
| JP2020505394A (ja) | 2017-01-26 | 2020-02-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | インダニルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 |
| JP2020514315A (ja) | 2017-01-26 | 2020-05-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110248929A (zh) | 2019-09-17 |
| EP3573959B1 (en) | 2021-07-28 |
| EP3573959A1 (en) | 2019-12-04 |
| CN110248929B (zh) | 2023-05-12 |
| US20190389815A1 (en) | 2019-12-26 |
| WO2018138028A1 (en) | 2018-08-02 |
| US10793530B2 (en) | 2020-10-06 |
| JP2020505393A (ja) | 2020-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7049349B2 (ja) | ベンジルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 | |
| JP7023969B2 (ja) | ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 | |
| JP7050792B2 (ja) | ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 | |
| JP7050791B2 (ja) | ベンジルオキシピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 | |
| JP7049353B2 (ja) | 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物 | |
| CN110088089B (zh) | 苄基氨基吡啶基环丙烷甲酸、药物组合物及其用途 | |
| JP6968181B2 (ja) | インダニルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 | |
| JP6816107B2 (ja) | インダニルアミノピリジルシクロプロパンカルボン酸、医薬組成物及びこれらの使用 | |
| JP5913752B2 (ja) | 新規インダニルオキシジヒドロベンゾフラニル酢酸 | |
| JP6163695B2 (ja) | 新しいインダニルオキシフェニルシクロプロパンカルボン酸 | |
| JP7008704B2 (ja) | インダニルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 | |
| JP2018526405A (ja) | ［｛［２，３−ジヒドロ−１Ｈ−インデン−１−イル］アミノ｝−２Ｈ，３Ｈ−フロ［３，２−ｂ］ピリジン−３−イル］酢酸、それらの医薬組成物および使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201124 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201124 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201126 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210922 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210927 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220224 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220325 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7049349 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |